The role of radiotracer imaging in Parkinson disease
Identifieur interne : 000921 ( PascalFrancis/Corpus ); précédent : 000920; suivant : 000922The role of radiotracer imaging in Parkinson disease
Auteurs : B. Ravina ; D. Eidelberg ; J. E. Ahlskog ; R. L. Albin ; D. J. Brooks ; M. Carbon ; V. Dhawan ; A. Feigin ; S. Fahn ; M. Guttman ; K. Gwinn-Hardy ; H. Mcfarland ; R. Innis ; R. G. Katz ; K. Kieburtz ; S. J. Kish ; N. Lange ; J. W. Langston ; K. Marek ; L. Morin ; C. Moy ; D. Murphy ; W. H. Oertel ; G. Oliver ; Y. Palesch ; W. Powers ; J. Seibyl ; K. D. Sethi ; C. W. Shults ; P. Sheehy ; A. J. Stoessl ; R. HollowaySource :
- Neurology [ 0028-3878 ] ; 2005.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Radiotracer imaging (RTI) of the nigrostriatal dopaminergic system is a widely used but controversial biomarker in Parkinson disease (PD). Here the authors review the concepts of biomarker development and the evidence to support the use of four radiotracers as biomarkers in PD: [18F]fluorodopa PET, (+)-[11C]dihydrotetrabenazine PET, [123I]β-CIT SPECT, and [18F]fluorodeoxyglucose PET. Biomarkers used to study disease biology and facilitate drug discovery and early human trials rely on evidence that they are measuring relevant biologic processes. The four tracers fulfill this criterion, although they do not measure the number or density of dopaminergic neurons. Biomarkers used as diagnostic tests, prognostic tools, or surrogate endpoints must not only have biologic relevance but also a strong linkage to the clinical outcome of interest. No radiotracers fulfill these criteria, and current evidence does not support the use of imaging as a diagnostic tool in clinical practice or as a surrogate endpoint in clinical trials. Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 05-0185260 INIST |
|---|---|
| ET : | The role of radiotracer imaging in Parkinson disease |
| AU : | RAVINA (B.); EIDELBERG (D.); AHLSKOG (J. E.); ALBIN (R. L.); BROOKS (D. J.); CARBON (M.); DHAWAN (V.); FEIGIN (A.); FAHN (S.); GUTTMAN (M.); GWINN-HARDY (K.); MCFARLAND (H.); INNIS (R.); KATZ (R. G.); KIEBURTZ (K.); KISH (S. J.); LANGE (N.); LANGSTON (J. W.); MAREK (K.); MORIN (L.); MOY (C.); MURPHY (D.); OERTEL (W. H.); OLIVER (G.); PALESCH (Y.); POWERS (W.); SEIBYL (J.); SETHI (K. D.); SHULTS (C. W.); SHEEHY (P.); STOESSL (A. J.); HOLLOWAY (R.) |
| AF : | National Institute of Neurological Disorders and Stroke/Bethesda, MD/Etats-Unis (1 aut., 11 aut., 12 aut., 20 aut., 21 aut., 22 aut., 24 aut., 30 aut.); National Institutes of Health/Bethesda, MD/Etats-Unis (2 aut., 6 aut., 7 aut., 8 aut.); Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System/Manhasset, NY/Etats-Unis (2 aut., 6 aut., 7 aut., 8 aut.); Department of Neurology, Mayo Clinic/Rochester, MN/Etats-Unis (3 aut.); Department of Neurology, University of Michigan and Ann Arbor VAMC GRECC/Ann Arbor, MI/Etats-Unis (4 aut.); Faculty of Medicine, Imperial College/London/Royaume-Uni (5 aut.); Department of Neurology, Columbia University/College of Physicians and Surgeons/New York, NY/Etats-Unis (9 aut.); Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health/Ontario/Canada (10 aut., 16 aut.); National Institute of Mental Health, National Institutes of Health/Bethesda, MD/Etats-Unis (13 aut.); US Food and Drug Administration/Rockville, MD/Etats-Unis (14 aut.); Department of Neurology, University of Rochester/NY/Etats-Unis (15 aut., 32 aut.); Departments of Psychiatry and Biostatistics, Harvard University Schools of Medicine and Public Health/Boston, MA/Etats-Unis (17 aut.); The Parkinson's Institute/Sunnyvale, CA/Etats-Unis (18 aut.); Institute for Neurodegenerative Disorders/New Haven, CT/Etats-Unis (19 aut., 27 aut.); Department of Neurology, Philipps University of Marburg/Marburg/Allemagne (23 aut.); Departments of Biometry and Epidemiology, Medical University of South Carolina/Charleston, SC/Etats-Unis (25 aut.); Department of Neurology, Washington University School of Medicine/St. Louis, MO/Etats-Unis (26 aut.); Department of Neurology, Medical College of Georgia/Augusta, GA/Etats-Unis (28 aut.); Department of Neuroscience, University of California, San Diego/CA/Etats-Unis (29 aut.); Pacific Parkinson's Research Center, University of British Columbia/Vancouver, British Columbia/Canada (31 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2005; Vol. 64; No. 2; Pp. 208-215; Bibl. 60 ref. |
| LA : | Anglais |
| EA : | Radiotracer imaging (RTI) of the nigrostriatal dopaminergic system is a widely used but controversial biomarker in Parkinson disease (PD). Here the authors review the concepts of biomarker development and the evidence to support the use of four radiotracers as biomarkers in PD: [18F]fluorodopa PET, (+)-[11C]dihydrotetrabenazine PET, [123I]β-CIT SPECT, and [18F]fluorodeoxyglucose PET. Biomarkers used to study disease biology and facilitate drug discovery and early human trials rely on evidence that they are measuring relevant biologic processes. The four tracers fulfill this criterion, although they do not measure the number or density of dopaminergic neurons. Biomarkers used as diagnostic tests, prognostic tools, or surrogate endpoints must not only have biologic relevance but also a strong linkage to the clinical outcome of interest. No radiotracers fulfill these criteria, and current evidence does not support the use of imaging as a diagnostic tool in clinical practice or as a surrogate endpoint in clinical trials. Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer. |
| CC : | 002B17; 002B17G; 002B24A06 |
| FD : | Système nerveux pathologie; Parkinson maladie |
| FG : | Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie |
| ED : | Nervous system diseases; Parkinson disease |
| EG : | Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease |
| SD : | Sistema nervioso patología; Parkinson enfermedad |
| LO : | INIST-6345.354000125640020070 |
| ID : | 05-0185260 |
Links to Exploration step
Pascal:05-0185260Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">The role of radiotracer imaging in Parkinson disease</title><author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B." last="Ravina">B. Ravina</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Eidelberg, D" sort="Eidelberg, D" uniqKey="Eidelberg D" first="D." last="Eidelberg">D. Eidelberg</name><affiliation><inist:fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ahlskog, J E" sort="Ahlskog, J E" uniqKey="Ahlskog J" first="J. E." last="Ahlskog">J. E. Ahlskog</name><affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Albin, R L" sort="Albin, R L" uniqKey="Albin R" first="R. L." last="Albin">R. L. Albin</name><affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Michigan and Ann Arbor VAMC GRECC</s1><s2>Ann Arbor, MI</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D. J." last="Brooks">D. J. Brooks</name><affiliation><inist:fA14 i1="06"><s1>Faculty of Medicine, Imperial College</s1><s2>London</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Carbon, M" sort="Carbon, M" uniqKey="Carbon M" first="M." last="Carbon">M. Carbon</name><affiliation><inist:fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dhawan, V" sort="Dhawan, V" uniqKey="Dhawan V" first="V." last="Dhawan">V. Dhawan</name><affiliation><inist:fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Feigin, A" sort="Feigin, A" uniqKey="Feigin A" first="A." last="Feigin">A. Feigin</name><affiliation><inist:fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S." last="Fahn">S. Fahn</name><affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Columbia University/College of Physicians and Surgeons</s1><s2>New York, NY</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name><affiliation><inist:fA14 i1="08"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1><s2>Ontario</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gwinn Hardy, K" sort="Gwinn Hardy, K" uniqKey="Gwinn Hardy K" first="K." last="Gwinn-Hardy">K. Gwinn-Hardy</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mcfarland, H" sort="Mcfarland, H" uniqKey="Mcfarland H" first="H." last="Mcfarland">H. Mcfarland</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Innis, R" sort="Innis, R" uniqKey="Innis R" first="R." last="Innis">R. Innis</name><affiliation><inist:fA14 i1="09"><s1>National Institute of Mental Health, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Katz, R G" sort="Katz, R G" uniqKey="Katz R" first="R. G." last="Katz">R. G. Katz</name><affiliation><inist:fA14 i1="10"><s1>US Food and Drug Administration</s1><s2>Rockville, MD</s2><s3>USA</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kieburtz, K" sort="Kieburtz, K" uniqKey="Kieburtz K" first="K." last="Kieburtz">K. Kieburtz</name><affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University of Rochester</s1><s2>NY</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>32 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kish, S J" sort="Kish, S J" uniqKey="Kish S" first="S. J." last="Kish">S. J. Kish</name><affiliation><inist:fA14 i1="08"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1><s2>Ontario</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lange, N" sort="Lange, N" uniqKey="Lange N" first="N." last="Lange">N. Lange</name><affiliation><inist:fA14 i1="12"><s1>Departments of Psychiatry and Biostatistics, Harvard University Schools of Medicine and Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Langston, J W" sort="Langston, J W" uniqKey="Langston J" first="J. W." last="Langston">J. W. Langston</name><affiliation><inist:fA14 i1="13"><s1>The Parkinson's Institute</s1><s2>Sunnyvale, CA</s2><s3>USA</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Marek, K" sort="Marek, K" uniqKey="Marek K" first="K." last="Marek">K. Marek</name><affiliation><inist:fA14 i1="14"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, CT</s2><s3>USA</s3><sZ>19 aut.</sZ><sZ>27 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Morin, L" sort="Morin, L" uniqKey="Morin L" first="L." last="Morin">L. Morin</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Moy, C" sort="Moy, C" uniqKey="Moy C" first="C." last="Moy">C. Moy</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Murphy, D" sort="Murphy, D" uniqKey="Murphy D" first="D." last="Murphy">D. Murphy</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W. H." last="Oertel">W. H. Oertel</name><affiliation><inist:fA14 i1="15"><s1>Department of Neurology, Philipps University of Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Oliver, G" sort="Oliver, G" uniqKey="Oliver G" first="G." last="Oliver">G. Oliver</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Palesch, Y" sort="Palesch, Y" uniqKey="Palesch Y" first="Y." last="Palesch">Y. Palesch</name><affiliation><inist:fA14 i1="16"><s1>Departments of Biometry and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, SC</s2><s3>USA</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Powers, W" sort="Powers, W" uniqKey="Powers W" first="W." last="Powers">W. Powers</name><affiliation><inist:fA14 i1="17"><s1>Department of Neurology, Washington University School of Medicine</s1><s2>St. Louis, MO</s2><s3>USA</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Seibyl, J" sort="Seibyl, J" uniqKey="Seibyl J" first="J." last="Seibyl">J. Seibyl</name><affiliation><inist:fA14 i1="14"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, CT</s2><s3>USA</s3><sZ>19 aut.</sZ><sZ>27 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sethi, K D" sort="Sethi, K D" uniqKey="Sethi K" first="K. D." last="Sethi">K. D. Sethi</name><affiliation><inist:fA14 i1="18"><s1>Department of Neurology, Medical College of Georgia</s1><s2>Augusta, GA</s2><s3>USA</s3><sZ>28 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shults, C W" sort="Shults, C W" uniqKey="Shults C" first="C. W." last="Shults">C. W. Shults</name><affiliation><inist:fA14 i1="19"><s1>Department of Neuroscience, University of California, San Diego</s1><s2>CA</s2><s3>USA</s3><sZ>29 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sheehy, P" sort="Sheehy, P" uniqKey="Sheehy P" first="P." last="Sheehy">P. Sheehy</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name><affiliation><inist:fA14 i1="20"><s1>Pacific Parkinson's Research Center, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>31 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Holloway, R" sort="Holloway, R" uniqKey="Holloway R" first="R." last="Holloway">R. Holloway</name><affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University of Rochester</s1><s2>NY</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>32 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0185260</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0185260 INIST</idno><idno type="RBID">Pascal:05-0185260</idno><idno type="wicri:Area/PascalFrancis/Corpus">000921</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">The role of radiotracer imaging in Parkinson disease</title><author><name sortKey="Ravina, B" sort="Ravina, B" uniqKey="Ravina B" first="B." last="Ravina">B. Ravina</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Eidelberg, D" sort="Eidelberg, D" uniqKey="Eidelberg D" first="D." last="Eidelberg">D. Eidelberg</name><affiliation><inist:fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ahlskog, J E" sort="Ahlskog, J E" uniqKey="Ahlskog J" first="J. E." last="Ahlskog">J. E. Ahlskog</name><affiliation><inist:fA14 i1="04"><s1>Department of Neurology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Albin, R L" sort="Albin, R L" uniqKey="Albin R" first="R. L." last="Albin">R. L. Albin</name><affiliation><inist:fA14 i1="05"><s1>Department of Neurology, University of Michigan and Ann Arbor VAMC GRECC</s1><s2>Ann Arbor, MI</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brooks, D J" sort="Brooks, D J" uniqKey="Brooks D" first="D. J." last="Brooks">D. J. Brooks</name><affiliation><inist:fA14 i1="06"><s1>Faculty of Medicine, Imperial College</s1><s2>London</s2><s3>GBR</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Carbon, M" sort="Carbon, M" uniqKey="Carbon M" first="M." last="Carbon">M. Carbon</name><affiliation><inist:fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Dhawan, V" sort="Dhawan, V" uniqKey="Dhawan V" first="V." last="Dhawan">V. Dhawan</name><affiliation><inist:fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Feigin, A" sort="Feigin, A" uniqKey="Feigin A" first="A." last="Feigin">A. Feigin</name><affiliation><inist:fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S." last="Fahn">S. Fahn</name><affiliation><inist:fA14 i1="07"><s1>Department of Neurology, Columbia University/College of Physicians and Surgeons</s1><s2>New York, NY</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Guttman, M" sort="Guttman, M" uniqKey="Guttman M" first="M." last="Guttman">M. Guttman</name><affiliation><inist:fA14 i1="08"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1><s2>Ontario</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gwinn Hardy, K" sort="Gwinn Hardy, K" uniqKey="Gwinn Hardy K" first="K." last="Gwinn-Hardy">K. Gwinn-Hardy</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mcfarland, H" sort="Mcfarland, H" uniqKey="Mcfarland H" first="H." last="Mcfarland">H. Mcfarland</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Innis, R" sort="Innis, R" uniqKey="Innis R" first="R." last="Innis">R. Innis</name><affiliation><inist:fA14 i1="09"><s1>National Institute of Mental Health, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Katz, R G" sort="Katz, R G" uniqKey="Katz R" first="R. G." last="Katz">R. G. Katz</name><affiliation><inist:fA14 i1="10"><s1>US Food and Drug Administration</s1><s2>Rockville, MD</s2><s3>USA</s3><sZ>14 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kieburtz, K" sort="Kieburtz, K" uniqKey="Kieburtz K" first="K." last="Kieburtz">K. Kieburtz</name><affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University of Rochester</s1><s2>NY</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>32 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Kish, S J" sort="Kish, S J" uniqKey="Kish S" first="S. J." last="Kish">S. J. Kish</name><affiliation><inist:fA14 i1="08"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1><s2>Ontario</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lange, N" sort="Lange, N" uniqKey="Lange N" first="N." last="Lange">N. Lange</name><affiliation><inist:fA14 i1="12"><s1>Departments of Psychiatry and Biostatistics, Harvard University Schools of Medicine and Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Langston, J W" sort="Langston, J W" uniqKey="Langston J" first="J. W." last="Langston">J. W. Langston</name><affiliation><inist:fA14 i1="13"><s1>The Parkinson's Institute</s1><s2>Sunnyvale, CA</s2><s3>USA</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Marek, K" sort="Marek, K" uniqKey="Marek K" first="K." last="Marek">K. Marek</name><affiliation><inist:fA14 i1="14"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, CT</s2><s3>USA</s3><sZ>19 aut.</sZ><sZ>27 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Morin, L" sort="Morin, L" uniqKey="Morin L" first="L." last="Morin">L. Morin</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Moy, C" sort="Moy, C" uniqKey="Moy C" first="C." last="Moy">C. Moy</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Murphy, D" sort="Murphy, D" uniqKey="Murphy D" first="D." last="Murphy">D. Murphy</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W. H." last="Oertel">W. H. Oertel</name><affiliation><inist:fA14 i1="15"><s1>Department of Neurology, Philipps University of Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Oliver, G" sort="Oliver, G" uniqKey="Oliver G" first="G." last="Oliver">G. Oliver</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Palesch, Y" sort="Palesch, Y" uniqKey="Palesch Y" first="Y." last="Palesch">Y. Palesch</name><affiliation><inist:fA14 i1="16"><s1>Departments of Biometry and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, SC</s2><s3>USA</s3><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Powers, W" sort="Powers, W" uniqKey="Powers W" first="W." last="Powers">W. Powers</name><affiliation><inist:fA14 i1="17"><s1>Department of Neurology, Washington University School of Medicine</s1><s2>St. Louis, MO</s2><s3>USA</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Seibyl, J" sort="Seibyl, J" uniqKey="Seibyl J" first="J." last="Seibyl">J. Seibyl</name><affiliation><inist:fA14 i1="14"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, CT</s2><s3>USA</s3><sZ>19 aut.</sZ><sZ>27 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sethi, K D" sort="Sethi, K D" uniqKey="Sethi K" first="K. D." last="Sethi">K. D. Sethi</name><affiliation><inist:fA14 i1="18"><s1>Department of Neurology, Medical College of Georgia</s1><s2>Augusta, GA</s2><s3>USA</s3><sZ>28 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Shults, C W" sort="Shults, C W" uniqKey="Shults C" first="C. W." last="Shults">C. W. Shults</name><affiliation><inist:fA14 i1="19"><s1>Department of Neuroscience, University of California, San Diego</s1><s2>CA</s2><s3>USA</s3><sZ>29 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sheehy, P" sort="Sheehy, P" uniqKey="Sheehy P" first="P." last="Sheehy">P. Sheehy</name><affiliation><inist:fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name><affiliation><inist:fA14 i1="20"><s1>Pacific Parkinson's Research Center, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>31 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Holloway, R" sort="Holloway, R" uniqKey="Holloway R" first="R." last="Holloway">R. Holloway</name><affiliation><inist:fA14 i1="11"><s1>Department of Neurology, University of Rochester</s1><s2>NY</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>32 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Neurology</title><title level="j" type="abbreviated">Neurology</title><idno type="ISSN">0028-3878</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neurology</title><title level="j" type="abbreviated">Neurology</title><idno type="ISSN">0028-3878</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Radiotracer imaging (RTI) of the nigrostriatal dopaminergic system is a widely used but controversial biomarker in Parkinson disease (PD). Here the authors review the concepts of biomarker development and the evidence to support the use of four radiotracers as biomarkers in PD: [<sup>18</sup>F]fluorodopa PET, (+)-[<sup>11</sup>C]dihydrotetrabenazine PET, [<sup>123</sup>I]β-CIT SPECT, and [<sup>18</sup>F]fluorodeoxyglucose PET. Biomarkers used to study disease biology and facilitate drug discovery and early human trials rely on evidence that they are measuring relevant biologic processes. The four tracers fulfill this criterion, although they do not measure the number or density of dopaminergic neurons. Biomarkers used as diagnostic tests, prognostic tools, or surrogate endpoints must not only have biologic relevance but also a strong linkage to the clinical outcome of interest. No radiotracers fulfill these criteria, and current evidence does not support the use of imaging as a diagnostic tool in clinical practice or as a surrogate endpoint in clinical trials. Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0></fA01><fA02 i1="01"><s0>NEURAI</s0></fA02><fA03 i2="1"><s0>Neurology</s0></fA03><fA05><s2>64</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>The role of radiotracer imaging in Parkinson disease</s1></fA08><fA11 i1="01" i2="1"><s1>RAVINA (B.)</s1></fA11><fA11 i1="02" i2="1"><s1>EIDELBERG (D.)</s1></fA11><fA11 i1="03" i2="1"><s1>AHLSKOG (J. E.)</s1></fA11><fA11 i1="04" i2="1"><s1>ALBIN (R. L.)</s1></fA11><fA11 i1="05" i2="1"><s1>BROOKS (D. J.)</s1></fA11><fA11 i1="06" i2="1"><s1>CARBON (M.)</s1></fA11><fA11 i1="07" i2="1"><s1>DHAWAN (V.)</s1></fA11><fA11 i1="08" i2="1"><s1>FEIGIN (A.)</s1></fA11><fA11 i1="09" i2="1"><s1>FAHN (S.)</s1></fA11><fA11 i1="10" i2="1"><s1>GUTTMAN (M.)</s1></fA11><fA11 i1="11" i2="1"><s1>GWINN-HARDY (K.)</s1></fA11><fA11 i1="12" i2="1"><s1>MCFARLAND (H.)</s1></fA11><fA11 i1="13" i2="1"><s1>INNIS (R.)</s1></fA11><fA11 i1="14" i2="1"><s1>KATZ (R. G.)</s1></fA11><fA11 i1="15" i2="1"><s1>KIEBURTZ (K.)</s1></fA11><fA11 i1="16" i2="1"><s1>KISH (S. J.)</s1></fA11><fA11 i1="17" i2="1"><s1>LANGE (N.)</s1></fA11><fA11 i1="18" i2="1"><s1>LANGSTON (J. W.)</s1></fA11><fA11 i1="19" i2="1"><s1>MAREK (K.)</s1></fA11><fA11 i1="20" i2="1"><s1>MORIN (L.)</s1></fA11><fA11 i1="21" i2="1"><s1>MOY (C.)</s1></fA11><fA11 i1="22" i2="1"><s1>MURPHY (D.)</s1></fA11><fA11 i1="23" i2="1"><s1>OERTEL (W. H.)</s1></fA11><fA11 i1="24" i2="1"><s1>OLIVER (G.)</s1></fA11><fA11 i1="25" i2="1"><s1>PALESCH (Y.)</s1></fA11><fA11 i1="26" i2="1"><s1>POWERS (W.)</s1></fA11><fA11 i1="27" i2="1"><s1>SEIBYL (J.)</s1></fA11><fA11 i1="28" i2="1"><s1>SETHI (K. D.)</s1></fA11><fA11 i1="29" i2="1"><s1>SHULTS (C. W.)</s1></fA11><fA11 i1="30" i2="1"><s1>SHEEHY (P.)</s1></fA11><fA11 i1="31" i2="1"><s1>STOESSL (A. J.)</s1></fA11><fA11 i1="32" i2="1"><s1>HOLLOWAY (R.)</s1></fA11><fA14 i1="01"><s1>National Institute of Neurological Disorders and Stroke</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>20 aut.</sZ><sZ>21 aut.</sZ><sZ>22 aut.</sZ><sZ>24 aut.</sZ><sZ>30 aut.</sZ></fA14><fA14 i1="02"><s1>National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="03"><s1>Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System</s1><s2>Manhasset, NY</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neurology, Mayo Clinic</s1><s2>Rochester, MN</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Neurology, University of Michigan and Ann Arbor VAMC GRECC</s1><s2>Ann Arbor, MI</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="06"><s1>Faculty of Medicine, Imperial College</s1><s2>London</s2><s3>GBR</s3><sZ>5 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Neurology, Columbia University/College of Physicians and Surgeons</s1><s2>New York, NY</s2><s3>USA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="08"><s1>Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health</s1><s2>Ontario</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>16 aut.</sZ></fA14><fA14 i1="09"><s1>National Institute of Mental Health, National Institutes of Health</s1><s2>Bethesda, MD</s2><s3>USA</s3><sZ>13 aut.</sZ></fA14><fA14 i1="10"><s1>US Food and Drug Administration</s1><s2>Rockville, MD</s2><s3>USA</s3><sZ>14 aut.</sZ></fA14><fA14 i1="11"><s1>Department of Neurology, University of Rochester</s1><s2>NY</s2><s3>USA</s3><sZ>15 aut.</sZ><sZ>32 aut.</sZ></fA14><fA14 i1="12"><s1>Departments of Psychiatry and Biostatistics, Harvard University Schools of Medicine and Public Health</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>17 aut.</sZ></fA14><fA14 i1="13"><s1>The Parkinson's Institute</s1><s2>Sunnyvale, CA</s2><s3>USA</s3><sZ>18 aut.</sZ></fA14><fA14 i1="14"><s1>Institute for Neurodegenerative Disorders</s1><s2>New Haven, CT</s2><s3>USA</s3><sZ>19 aut.</sZ><sZ>27 aut.</sZ></fA14><fA14 i1="15"><s1>Department of Neurology, Philipps University of Marburg</s1><s2>Marburg</s2><s3>DEU</s3><sZ>23 aut.</sZ></fA14><fA14 i1="16"><s1>Departments of Biometry and Epidemiology, Medical University of South Carolina</s1><s2>Charleston, SC</s2><s3>USA</s3><sZ>25 aut.</sZ></fA14><fA14 i1="17"><s1>Department of Neurology, Washington University School of Medicine</s1><s2>St. Louis, MO</s2><s3>USA</s3><sZ>26 aut.</sZ></fA14><fA14 i1="18"><s1>Department of Neurology, Medical College of Georgia</s1><s2>Augusta, GA</s2><s3>USA</s3><sZ>28 aut.</sZ></fA14><fA14 i1="19"><s1>Department of Neuroscience, University of California, San Diego</s1><s2>CA</s2><s3>USA</s3><sZ>29 aut.</sZ></fA14><fA14 i1="20"><s1>Pacific Parkinson's Research Center, University of British Columbia</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>31 aut.</sZ></fA14><fA20><s1>208-215</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>6345</s2><s5>354000125640020070</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>60 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0185260</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Neurology</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Radiotracer imaging (RTI) of the nigrostriatal dopaminergic system is a widely used but controversial biomarker in Parkinson disease (PD). Here the authors review the concepts of biomarker development and the evidence to support the use of four radiotracers as biomarkers in PD: [<sup>18</sup>F]fluorodopa PET, (+)-[<sup>11</sup>C]dihydrotetrabenazine PET, [<sup>123</sup>I]β-CIT SPECT, and [<sup>18</sup>F]fluorodeoxyglucose PET. Biomarkers used to study disease biology and facilitate drug discovery and early human trials rely on evidence that they are measuring relevant biologic processes. The four tracers fulfill this criterion, although they do not measure the number or density of dopaminergic neurons. Biomarkers used as diagnostic tests, prognostic tools, or surrogate endpoints must not only have biologic relevance but also a strong linkage to the clinical outcome of interest. No radiotracers fulfill these criteria, and current evidence does not support the use of imaging as a diagnostic tool in clinical practice or as a surrogate endpoint in clinical trials. Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC02 i1="03" i2="X"><s0>002B24A06</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>04</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fN21><s1>122</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 05-0185260 INIST</NO><ET>The role of radiotracer imaging in Parkinson disease</ET><AU>RAVINA (B.); EIDELBERG (D.); AHLSKOG (J. E.); ALBIN (R. L.); BROOKS (D. J.); CARBON (M.); DHAWAN (V.); FEIGIN (A.); FAHN (S.); GUTTMAN (M.); GWINN-HARDY (K.); MCFARLAND (H.); INNIS (R.); KATZ (R. G.); KIEBURTZ (K.); KISH (S. J.); LANGE (N.); LANGSTON (J. W.); MAREK (K.); MORIN (L.); MOY (C.); MURPHY (D.); OERTEL (W. H.); OLIVER (G.); PALESCH (Y.); POWERS (W.); SEIBYL (J.); SETHI (K. D.); SHULTS (C. W.); SHEEHY (P.); STOESSL (A. J.); HOLLOWAY (R.)</AU><AF>National Institute of Neurological Disorders and Stroke/Bethesda, MD/Etats-Unis (1 aut., 11 aut., 12 aut., 20 aut., 21 aut., 22 aut., 24 aut., 30 aut.); National Institutes of Health/Bethesda, MD/Etats-Unis (2 aut., 6 aut., 7 aut., 8 aut.); Center for Neurosciences, Institute for Medical Research, North Shore-Long Island Jewish Health System/Manhasset, NY/Etats-Unis (2 aut., 6 aut., 7 aut., 8 aut.); Department of Neurology, Mayo Clinic/Rochester, MN/Etats-Unis (3 aut.); Department of Neurology, University of Michigan and Ann Arbor VAMC GRECC/Ann Arbor, MI/Etats-Unis (4 aut.); Faculty of Medicine, Imperial College/London/Royaume-Uni (5 aut.); Department of Neurology, Columbia University/College of Physicians and Surgeons/New York, NY/Etats-Unis (9 aut.); Human Neurochemical Pathology Laboratory, Center for Addiction and Mental Health/Ontario/Canada (10 aut., 16 aut.); National Institute of Mental Health, National Institutes of Health/Bethesda, MD/Etats-Unis (13 aut.); US Food and Drug Administration/Rockville, MD/Etats-Unis (14 aut.); Department of Neurology, University of Rochester/NY/Etats-Unis (15 aut., 32 aut.); Departments of Psychiatry and Biostatistics, Harvard University Schools of Medicine and Public Health/Boston, MA/Etats-Unis (17 aut.); The Parkinson's Institute/Sunnyvale, CA/Etats-Unis (18 aut.); Institute for Neurodegenerative Disorders/New Haven, CT/Etats-Unis (19 aut., 27 aut.); Department of Neurology, Philipps University of Marburg/Marburg/Allemagne (23 aut.); Departments of Biometry and Epidemiology, Medical University of South Carolina/Charleston, SC/Etats-Unis (25 aut.); Department of Neurology, Washington University School of Medicine/St. Louis, MO/Etats-Unis (26 aut.); Department of Neurology, Medical College of Georgia/Augusta, GA/Etats-Unis (28 aut.); Department of Neuroscience, University of California, San Diego/CA/Etats-Unis (29 aut.); Pacific Parkinson's Research Center, University of British Columbia/Vancouver, British Columbia/Canada (31 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2005; Vol. 64; No. 2; Pp. 208-215; Bibl. 60 ref.</SO><LA>Anglais</LA><EA>Radiotracer imaging (RTI) of the nigrostriatal dopaminergic system is a widely used but controversial biomarker in Parkinson disease (PD). Here the authors review the concepts of biomarker development and the evidence to support the use of four radiotracers as biomarkers in PD: [<sup>18</sup>F]fluorodopa PET, (+)-[<sup>11</sup>C]dihydrotetrabenazine PET, [<sup>123</sup>I]β-CIT SPECT, and [<sup>18</sup>F]fluorodeoxyglucose PET. Biomarkers used to study disease biology and facilitate drug discovery and early human trials rely on evidence that they are measuring relevant biologic processes. The four tracers fulfill this criterion, although they do not measure the number or density of dopaminergic neurons. Biomarkers used as diagnostic tests, prognostic tools, or surrogate endpoints must not only have biologic relevance but also a strong linkage to the clinical outcome of interest. No radiotracers fulfill these criteria, and current evidence does not support the use of imaging as a diagnostic tool in clinical practice or as a surrogate endpoint in clinical trials. Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer.</EA><CC>002B17; 002B17G; 002B24A06</CC><FD>Système nerveux pathologie; Parkinson maladie</FD><FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG><ED>Nervous system diseases; Parkinson disease</ED><EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG><SD>Sistema nervioso patología; Parkinson enfermedad</SD><LO>INIST-6345.354000125640020070</LO><ID>05-0185260</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000921 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000921 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:05-0185260
|texte= The role of radiotracer imaging in Parkinson disease
}}
| This area was generated with Dilib version V0.6.29. |  |